Viewing Study NCT03534492


Ignite Creation Date: 2025-12-24 @ 3:35 PM
Ignite Modification Date: 2025-12-25 @ 1:47 PM
Study NCT ID: NCT03534492
Status: COMPLETED
Last Update Posted: 2020-04-06
First Post: 2018-05-11
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
Sponsor: Spanish Oncology Genito-Urinary Group
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module